February 14, 2018
SpectraCures CEO Masoud Khayyami will present the company, including the status of the ongoing clinical study, at G&W Capital Market Day on February 23th, at 10:00 AM.
Location: Berns Salonger, Kammarsalen, Berzelii Park, Stockholm
The presentation can also be followed via webcast at https://tv.streamfabriken.com/2018-02-23-spectracure
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.
Information contained on this page is provided by an independent third-party content provider. This Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact support [at] perpetualwire.com.